Czech National Bank Purchases 1,338 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Czech National Bank increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,164 shares of the biopharmaceutical company's stock after acquiring an additional 1,338 shares during the period. Czech National Bank's holdings in Regeneron Pharmaceuticals were worth $15,326,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Brighton Jones LLC lifted its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the period. Mediolanum International Funds Ltd lifted its position in Regeneron Pharmaceuticals by 5.3% during the 4th quarter. Mediolanum International Funds Ltd now owns 4,449 shares of the biopharmaceutical company's stock valued at $3,118,000 after purchasing an additional 224 shares during the period. Caprock Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 27.1% in the 4th quarter. Caprock Group LLC now owns 1,647 shares of the biopharmaceutical company's stock valued at $1,173,000 after purchasing an additional 351 shares during the last quarter. Independence Bank of Kentucky grew its position in shares of Regeneron Pharmaceuticals by 16.1% during the 4th quarter. Independence Bank of Kentucky now owns 216 shares of the biopharmaceutical company's stock worth $154,000 after buying an additional 30 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 279.8% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 12,257 shares of the biopharmaceutical company's stock valued at $8,731,000 after buying an additional 9,030 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.4%

Regeneron Pharmaceuticals stock traded down $1.86 during midday trading on Thursday, reaching $483.07. The stock had a trading volume of 1,790,802 shares, compared to its average volume of 856,101. The stock has a market capitalization of $52.15 billion, a P/E ratio of 12.62, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The firm's fifty day simple moving average is $572.23 and its 200-day simple moving average is $659.43. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the firm posted $9.55 earnings per share. The firm's quarterly revenue was down 3.7% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.73%. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a report on Monday. The Goldman Sachs Group decreased their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. UBS Group dropped their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a report on Thursday. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Finally, Truist Financial lowered their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $844.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.